CD8A and neoplasm: Furthermore, therapies using Fc domain enhanced anti-TREM2 monoclonal antibody have been developed to promote anti-tumor immunity by eliminating and modulating TAM populations, which leads to enhanced CD8+ TIL infiltration and effector function 195.